Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure.

Trial Profile

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms DEC-MDS
  • Most Recent Events

    • 20 Oct 2013 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
    • 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 05 Oct 2013 Planned end date changed from 30 Sep 2013 to 14 Oct 2013 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top